Session » 2013 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 2722

In Vivo Administration Of MiR-146a Protects C57BL/6 Mice From Pristane-Induced Pulmonary Hemorrhage Via Suppressing Type I Interferon Response

Abstract Number: 2723

Role Of Interferon-Inducible RNA-Dependent Protein Kinase In The Pathogenesis Of Systemic Lupus Erythematosus

Abstract Number: 2724

cAMP Responsive Element Modulator (CREM)α Governs CD8 Expression and Contributes to the Generation of CD3⁺CD4^–CD8^– T Cells in Lupus

Abstract Number: 2725

Regulation Of Aberrant CD4 T Cell Activation By Suppressor Of Cytokine Signaling-1 (SOCS1) Mimetic Peptide, Has Relevance To Human Systemic Lupus Erythematosus

Abstract Number: 2726

A Polymorphism In The Mif Gene Is Associated With Cardiovascular Morbidity In Systemic Lupus Erythematosus – a Pilot Study

Abstract Number: 2727

Immunologic and Inflammatory Markers Of Impending Disease Flare In Systemic Lupus Erythematosus Patients Not Taking Immunosuppressive Medications In The Biomarkers Of Lupus Disease (BOLD) Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.